Xceleron

Xceleron's experience is particularly valuable because the characteristics of many contemporary small molecules (low solubility, long half-life, and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic properties are crucial for the cost-effectiveness of clinical development.